More on SNDX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $13.57 |
|
|||
| Open | $13.60 | ||||
| 52 Wk High | $18.03 | ||||
| 52 Wk Low | $8.97 | ||||
| Day High | $13.60 | ||||
| Day Low | $13.20 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 4,249,691 | ||||
- Syndax’s Revuforj® (revumenib) Named to TIME’s Best Inventions of 2026 List
- Stifel Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
- Syndax Pharmaceuticals (SNDX) call put ratio 1 call 1.3 puts into share price lower before the bell
- Citi reiterates Buy rating on Syndax Pharmaceuticals after stock drop
- Syndax Pharmaceuticals stock tumbles on failed IPF trial
- Syndax's axatilimab fails IPF trial's primary endpoint
- Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
- H.C. Wainwright Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- H.C. Wainwright Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
Entities mentioned with SNDX
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
